NCT06947330 Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy
| NCT ID | NCT06947330 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Kholoud Usama |
| Condition | Modified Radical Mastectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-03-03 |
| Primary Completion | 2026-03-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 100 participants in total. It began in 2025-03-03 with a primary completion date of 2026-03-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare Ultrasound Guided Erector Spinae and Ultrasound Guided Serratus Anterior Plane Block post Modified Radical Mastectomy in adult females. the main questions it aims to answer are: * Which of the two blocks has a better analgesic effect? * Which of the two blocks is safer as regards inducing a pneumothorax and affecting the hemodynamics? Participants: * Will be divided into two groups after signing the informed consent. * After being anesthetized and before surgical incision; the blocks will be given to the patient. * Lung Ultrasound will be done for each patient to rule out pnemothorax once before the surgery and another after the end of surgery while the patient is being anesthetized. * Patients that will experience pneuomothorax will be excluded from the study, and will be treated according to its size. * Follow up of the patient for 24 hours postoperative to record the VAS score continuously, with giving increments of pethidine intravenously to relief pain.
Eligibility Criteria
Inclusion Criteria: * ASA Physical Status II, or III. * Age 21 - 65 years. * Female gender Exclusion Criteria: * ASA IV, V, VI. * Infection at site of block. * Coagulopathy, or patients on antiplatelets, or anticoagulants. * Previous anesthetic allergy to bupivacaine. * Distant organ metastasis. * Male gender.
Frequently Asked Questions
Who can join the NCT06947330 clinical trial?
This trial is open to female participants only, aged 21 Years or older, up to 65 Years, studying Modified Radical Mastectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06947330 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 100 participants.
Is NCT06947330 currently recruiting?
Yes, NCT06947330 is actively recruiting participants. Visit ClinicalTrials.gov or contact Kholoud Usama to inquire about joining.
Where is the NCT06947330 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06947330 clinical trial?
NCT06947330 is sponsored by Kholoud Usama. The trial plans to enroll 100 participants.